Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Higher TGF-β signaling may increase skin cancer risk in organ transplant recipients.

BMS-470539 reduces skin fibrosis and inflammation.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Patients with melanoma who saw dermatologists and were from higher-income areas were more likely to have follow-up visits, which was linked to lower mortality.

Loss of the p53 gene alone causes tumors, and losing both p53 and Rb genes speeds up aggressive skin cancer.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

Asiasari radix extract may be a potential treatment for melanoma because it selectively triggers cell death in melanoma cells by affecting p53 regulation.

Skin tumor regression is helped by retinoic acid signaling blocking Wnt signaling.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

Baricitinib was effective in treating both early and late onset alopecia areata.

Improved CRBN ligands make protein degraders more effective and drug-like.

New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.

Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.

A new genetic mutation linked to CARASIL syndrome and small artery disease was found in a Chinese family.

Vorasidenib can cause unusual hair growth.

JAK inhibitors show promise for treating various skin diseases.

A PIK3CA mutation in Schwann cells causes severe nerve damage and increased glycolysis, but early treatment can help.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.

Rash from EGFRI treatment can indicate both side effects and treatment effectiveness.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Nilotinib can cause skin issues like red bumps and hair loss.